Stay updated on Efficacy Safety in Primary IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.

Latest updates to the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.3.4 is now displayed on the page, replacing the previous v3.3.3.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedA new Locations section has been added and California is now listed under locations, replacing the previous California Locations grouping. The HHS Vulnerability Disclosure footer link has been removed and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check53 days agoChange DetectedRevision: v3.3.2 replaces v3.2.0 in the page footer. There are no changes to the study data or visible content.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved the site-wide banner about government funding lapses and NIH operating status; core study details and content remain unchanged.SummaryDifference0.3%

- Check82 days agoChange DetectedDifference0.4%

- Check104 days agoChange Detected- Added a government funding lapse notice and operating-status guidance, and confirmed the NIH Clinical Center is open with sources. - Version updated from v3.1.0 to v3.2.0.SummaryDifference4%

Stay in the know with updates to Efficacy Safety in Primary IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.